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Purpose: Oguchi’s disease is a rare autosomal recessive disease and known to be caused by mutations in the rhodopsin
kinase (GRK1) gene or the arrestin (SAG) gene. SAG contains 16 exons and encodes a protein with 405 amino acids. This
study was to identify the underlying genetic defects in a non-consanguineous Chinese family with Oguchi’s disease.
Methods: Ophthalmologic examinations including fundus photography and electroretinography (ERG) were performed
on all family members. All exons of the GRK1 gene and the SAG gene were amplified with PCR and directly sequenced.
Quantitative real-time PCR (qPCR) was performed to screen heterozygous deletions/duplications in the SAG gene. Long-
range PCR and direct sequencing were further performed to define the breakpoints.
Results: The patient had characteristic clinical features of Oguchi’s disease, including night blindness, normal vision
fields, typical fundus appearance with the Mizuo-Nakamura phenomenon, nearly undetectable rod b waves in the scotopic
0.01 ERGs, and nearly “negative” scotopic 3.0 ERGs. No mutations were found in the GRK1 gene. A heterozygous
nonsense Arg193stop (R193X) mutation was found in the SAG gene in the patient and the unaffected mother. No
pathogenic SAG mutations were found in the unaffected father. qPCRs showed a heterozygous deletion encompassing
exon 2 of the SAG gene in the patient and the unaffected father. Long-range PCR and direct sequencing verified the deletion
and revealed the breakpoints of the deletion, skipping a 3,224-bp fragment of the SAG gene. The deletion was not detected
in 96 unrelated healthy controls. This deletion was predicted to eliminate the exon 2 and the AUG initiate codon in the
mature SAG mRNA and cause no production of the SAG protein or low-level production of a non-functional truncated
protein lacking 134 amino acids in the NH2 terminus.
Conclusions: Compound heterozygosity of a nonsense R193X mutation and a heterozygous deletion of 3,224 bp
encompassing exon 2 in the SAG gene is the cause of Oguchi’s disease in this Chinese family. qPCR analysis should be
performed if there is a negative result of the mutation screening of the SAG gene in patients with Oguchi’s disease.
Oguchi’s  disease  (OMIM  258100)  is  a  rare  form  of
stationary  night  blindness  with  autosomal  recessive
inheritance, characterized by a typical clinical feature called
the  Mizuo-Nakamura  phenomenon  in  which  the  golden-
yellow discoloration of the fundus disappears in the dark-
adapted condition and reappears shortly after exposure to light
[1]. In addition, patients with Oguchi’s disease usually have
night blindness but normal color vision, visual acuity, and
visual field [2]. Electroretinographic examinations showed
reduced or no rod functions with normal cone functions [2,
3].
Two causative genes have been reported for Oguchi’s
disease: the arrestin (SAG; OMIM 181031) gene [1] and the
rhodopsin  kinase  (GRK1;  OMIM  180381)  gene  [4].
Beginning in 1995 with the first report on a homozygous
SAG frameshift 926delA (formerly referred to as 1147delA)
[5-7] mutation in five of six unrelated Japanese patients [1],
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more SAG mutations have been found in Oguchi’s disease,
including  an  additional  homozygous  frameshift  926delA
mutation  in  seven  other  Japanese  families  [8-12],  a
homozygous nonsense Arg193stop (R193X) mutation in an
Indian family [13], a compound heterozygous mutation of a
nonsense  R175X  mutation  plus  a  frameshift  926delA
mutation  in  a  Japanese  family  [14],  and  a  homozygous
nonsense R292X mutation in a Japanese family [14] and in a
South  Asian  family  [15].  Recently,  an  additional
heterozygous  frameshift  926delA  mutation  without
identification of the other mutation in another allele during
mutation  screening  of  the  SAG  gene  was  reported  in  a
Japanese  patient  [16],  suggesting  that  other  types  of
mutations, undetectable with mutation screening of the SAG
gene, may exist.
In this study, we report a heterozygous nonsense R193X
mutation  and  a  novel  heterozygous  deletion  of  3,224  bp
encompassing exon 2 in the SAG gene in a Chinese family.
The deletion was identified using quantitative real-time PCR
(qPCR). To our knowledge, this is the first case found in a
Chinese family and is the first report of a novel heterozygous
deletion in the SAG gene.
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528METHODS
A Chinese family with a 13-year-old female patient and her
unaffected  parents  participated  in  this  study.  This  study
conformed to the tenets of the Declaration of Helsinki, and the
research protocol was approved by the Ethics Committee of
the  Reproductive  and  Genetic  Hospital  of  Citic-Xiangya
(Changsha, P.R. China). Informed consent was obtained from
all family members after an explanation of the purpose of this
study was provided.
Clinical examinations: Family members were clinically
examined at the Department of Ophthalmology, the Second
Affiliated  Xiangya  Hospital  of  Central  South  University.
Ophthalmologic examinations included best-corrected visual
acuity  (BCVA),  slit  lamp  biomicroscopy,  fundus
photography,  kinetic  perimetry,  and  electroretinography.
Kinetic perimetry was performed on a Twinfield perimeter
(Oculus  Inc.,  Wetzlar,  Germany)  using  defined  stimuli
according  to  the  Goldmann  standard.  Standard  full-field
electroretinograms  (ERGs)  were  elicited  with  Ganzfeld
stimuli after 30 min of dark adaptation using the commercial
ERG  system  (RetiPort32;  Roland  Consult  Systems,
Bradenburg,  Germany)  according  to  the  guidelines  of  the
International Society for Clinical Electrophysiology of Vision
(ISCEV)(standard flash, 3 cd·s·m−2) [17]. The stimuli were
0.0095 cd·s·m−2 for rod stimulation (Scotopic 0.01 ERG) and
3 cd·s·m−2 for other standard responses (including scotopic
3.0 ERG, photopic 3.0 ERG, and photopic 3.0 flicker). For
photopic ERG, the background luminance was set at 34 cd·m
−2.
Mutation  screening:  All  exons  of  the  GRK1  gene,
including exon/intron boundaries, were amplified with PCR
and directly sequenced as previously described [18]. All exons
of the SAG gene with exon/intron boundaries were amplified
with PCR using primers (Table 1) designed by Primer 3 and
checked by NCBI BLAST for specificity followed by direct
sequencing for mutation screening.
TABLE 1. PRIMERS FOR MUTATION SCREENING OF SAG.
Exon F/R Primer Sequence (5′-3′) PCR size (bp)
1 F GCTTGCATAACACCAGGTTCATC 750
  R CCGCTCACTCCAAGTCTCC  
2 F TTGTCTTACCTTTCTCCAACCC 255
  R CCCTCAAAGAGTTTTGATGTTG  
3 F CATGGATGCCTTAGCTTAGC 217
  R TAGATTATTAGCAAGGCCAG  
4 F GGTTTCTTTCATCTTCTCCA 189
  R CTCTCCTTCCATGTAAATG  
5 F TTGAAAACCCGTGTTCGCTG 366
  R TCTATCCCCTTTCCTTTGCC  
6 F ATATTACTTAATGGAACAGC 213
  R ACAGAGTAAAACCCTGTTTC  
7 F CATGTGCCCTGTGTGAGGTG 246
  R CCACAGAGACAAGGTGGAGG  
8 F GGAGAGAACAGAAGCCTCCC 300
  R ATGTAGTTAAGGGCTGGGGC  
9 F ATTCCAGTGAAAGGGATTGAG 269
  R ATCAGACCAGAGAAGTGACC  
10 F AGGAGAGACCAGCGTGTACC 240
  R CAGCAATAAACGGCGAGAAAC  
11 F GGTCCATGGCAGCTTTGATG 217
  R CTTATTCCCTGAGCCTCGAG  
12 F AAAGGCTGCCCATCTGCTC 244
  R CCTTGCTTTCTGTCTCCCAG  
13 F GAGCTGGGCTGTGTCCTGCC 173
  R AAGTTTGCTGCCTTTGATAT  
14 F GCAGCCATAGGTCTTTGCTG 258
  R ATGGAATCTCTTACACCTGG  
15 F TCAAATTGTAAAGTCACCTAAAAGG 205
  R AAGAGGGTTTTGTGCTGGAG  
16 F CTTGATCAGTTCCTTCGTTGC 276
  R GACTAAACTGTGGGGCTTTGC  
           F, Forward; R, Reverse.
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(qPCR): qPCR was performed to detect exonic deletions/
duplications and fine mapping of the breakpoints. Primers
were designed with an amplicon size of less than 300 bp
(Table 2). For fine mapping of the heterozygous deletion
encompassing exon 2 identified in qPCR, additional primer
pairs were designed and named In1 (located in intron 1), In2–
1, In2–2, In2–3, In2–4, and In2–5 (located in intron 2; Table
2). The albumin (ALB) gene was used as the reference gene
[19]. The qPCR reactions were performed in 10 µl volume
containing  1×iQTM  SYBR®  Green  Supermix  (Bio-Rad
Laboratories,  Inc.,  Hercules,  CA),  primers  at  a  final
concentration  of  0.25  μM  each  and  genomic  DNA  at  a
concentration of 5 ng/μl. The qPCR reactions were run in the
7500  Real-time  PCR  system  (Applied  Biosystems,  Foster
City, CA). Cycling conditions were 95 °C for 10 min, and 40
cycles of 95 °C for 15 s and 60 °C for 1 min. A melting curve
analysis of products was performed routinely following the
amplification  to  test  the  specificity  of  the  PCR  products.
Genomic  DNA  from  a  normal  individual  was  used  as  a
deletion-negative  control  (the  calibrator  sample)  to
normalization.  Two  independent  experiments  were
performed. Quantitative PCR data were analyzed with the
comparative  threshold  cycle  method  [20,21].  A  relative
quantity of about 1 in a normal sample, about 0.5 in a sample
with a heterozygous SAG exon deletion, and about 1.5 in a
sample  with  a  heterozygous  SAG  exon  duplication  was
expected.
Long-range polymerase chain reaction: To validate the
heterozygous deletion detected with qPCR analysis, a long-
range PCR approach was performed using the primers In1-F
and In2–4-R (Table 2). The PCR conditions were 95 °C for 5
min, and 35 cycles of 94 °C for 30 s, 60 °C for 30 s, and 68 °C
for 1 min, followed by the final extension at 68 °C for 5 min.
The purified PCR products were directly sequenced.
RESULTS
Clinical findings: The proband was a 13-year-old girl who had
night blindness since early childhood. Her BCVA was 1.5 in
each eye. The refractive errors were −3.50 −0.50×180° in the
right  eye  and  −3.75  −0.50×180°  in  the  left  eye.  Fundus
examinations  showed  the  characteristic  golden-yellow
discoloration  in  both  eyes  and  the  Mizuo-Nakamura
phenomenon, in which the golden-yellow discoloration of the
fundus  (Figure  1A)  disappeared  after  prolonged  dark
adaptation  (Figure  1B).  Neither  vascular  attenuation  nor
retinal degeneration was seen throughout the retina, and no
maculopathy was observed. The visual fields of both eyes
were within normal limits. The full-field scotopic 0.01 ERGs
showed undetectable rod b waves in the patient. The scotopic
3.0  ERGs  showed  a  “negative”  configuration  with  a
significantly reduced a wave and a nearly absent b wave in
both eyes. The photopic 3.0 ERGs and photopic 3.0 flickers
seemed  almost  normal  (Figure  2).  The  girl  was  the  first
offspring of an unaffected non-consanguineous couple, and
no family history was found in the family pedigree (Figure
3A).
TABLE 2. PRIMERS FOR QUANTITATIVE PCR ANALYSIS OF SAG
Name F/R Primer sequence PCR size (bp)
Exon1 F CCTGGTTGGTGACAAATCACAAG 184
  R CCGCTCACTCCAAGTCTCC  
Exon 2 F ACACCCCAAGGTGGTAGAAGTT 123
  R CACCACTCACCGATTTGTCC  
Exon5 F CTCCCTTGCAGTGTATGTCAC 215
  R AGTCACCCACCGTCAGGAGA  
In1 F GAAAACAGTCTTTGCGAAGTGG 177
  R ACACCTTGCCAGGGAGTCTA  
In2–1 F TTCTTCTCCGTGCACCTACC 191
  R AGCTATCCACAGAGGCTGGA  
In2–2 F CCTCACAGGTGGGAAAAGAG 160
  R GCTGGAGGATGAAGGTCAAAG  
In2–3 F AACCACCAACTACCCTCGAC 171
  R AAGGGGAGAACCAGTTAGGC  
In2–4 F CCACAGAGAAGGAGTGAGCA 78
  R CTGCCTTGCAGGAATGGTAAC  
In2–5 F ACACCACCCAGGCTAGTGAG 149
  R CTGTGCCCTCTAGGTTACTCG  
          Quantitative PCR primers for other SAG exons are the same as the primers used for mutation screening except exon 1, exon 2,
          and exon 5 shown in this table. F, Forward; R, Reverse.
Molecular Vision 2012; 18:528-536 <http://www.molvis.org/molvis/v18/a58> © 2012 Molecular Vision
530Molecular genetic findings: No mutations in the GRK1 gene
were found in the patient. Mutation screening of the SAG gene
revealed  a  heterozygous  nonsense  mutation  R193X  (c.
577C>T;  Figure  3B,C),  and  three  heterozygous  single
nucleotide  polymorphisms  (SNPs,  recorded  in  the  SNP
database [build 130]) including IVS6–18G>C, IVS9+31T>G,
and c.1207G>A (V430I; Figure 3B) in the patient. Among
four nucleotide changes, the heterozygous nucleotide change
IVS9+31T>G was seen in both parents while the other three
changes were found only in the mother, suggesting those
changes  were  inherited  from  the  mother  (Figure  3B).  No
putative pathogenic mutation was identified in the father.
The existence of four heterozygous nucleotide changes
in the patient suggested that exon 7, exon 8, exon 9, and exon
16 were deletion-negative. qPCR analysis of the other 12
exons  of  the  SAG  gene  was  performed  and  revealed  a
heterozygous deletion of the SAG exon 2 in the patient and
her unaffected father (Figure 4A). Fine mapping of the exon
2 deletion with qPCR analysis using the primers including In1,
In2–1,  In2–2,  In2–3,  In2–4,  and  In2–5  revealed  the
heterozygous deletion involving In2–1, In2–2, and In2–3 in
the patient and her father (Figure 4B, Figure 5A).
Long-range PCR using the primers In1-F and In2–4-R
amplified a shortened fragment of about 1,500 bp in the patient
and her father (Figure 5B). Direct sequencing of the long-
Figure  1.  Fundus  photographs  before
and  after  dark  adaption  in  a  Chinese
patient with Oguchi’s disease. A: The
fundus  photographs  revealed  an
abnormal  golden-yellow  reflex  in  the
light-adapted  state.  B:  This  abnormal
reflex  disappeared  after  4  h  of  dark-
adaptation. The left eye is shown.
Figure 2. Full-field electroretinograms (ERGs) of a normal person and a patient with Oguchi’s disease. The rod b waves were nearly
undetectable in scotopic 0.01 ERGs. The scotopic 3.0 ERGs show a significant reduction in a-wave amplitudes and a near total absence of b
waves. The photopic 3.0 ERGs and photopic 3.0 flicker ERGs were almost normal.
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skipping a 3,224-bp fragment of the SAG gene. The 5′-end of
the breakpoint was located in the intron 1/exon 2 boundary,
and the 3′-end of the breakpoint was located in the intron 2,
3,122 bp downstream of exon 2 (IVS2+3122; Figure 5C). No
shortened fragment was seen in 96 unrelated healthy controls.
DISCUSSION
Oguchi’s  disease  is  a  rare  autosomal  recessive  inherited
disease.  Patients  usually  have  typical  clinical  features
including night blindness, typical fundus changes called the
Mizuo-Nakamura  phenomenon,  and  characteristic  ERGs
revealing  reduced  or  no  rod  function  with  normal  cone
function [1-3]. The patient described here could be clinically
diagnosed  with  Oguchi’s  disease  according  to  the  typical
ophthalmologic features revealed by clinical examinations.
Two causative genes, SAG [1] and GRK1 [4], have been
reported  for  Oguchi’s  disease.  To  date,  only  four  SAG
mutations including 926delA, R193X, R175X, and R292X
have been reported in 16 Japanese families [1,8-12,14,16],
one Indian family [13], and one South Asian family [15] with
Oguchi’s disease. The most recent report of Oguchi’s disease
was identified in a Japanese patient with only one allele of the
frameshift 926delA mutation [16], suggesting that other types
of mutation, undetectable by mutation screening of the coding
regions of the SAG gene, may exist in the other allele of the
SAG gene in the patient.
In our study, only one heterozygous nonsense R193X
mutation  was  identified  in  the  patient  and  her  mother  by
mutation screening of the coding regions of the SAG gene. The
homozygous nonsense R193X mutation has been reported in
only one Indian family with Oguchi’s disease. qPCR analysis
followed by long-range PCR revealed a novel heterozygous
deletion of 3,224 bp, encompassing exon 2 and partial intron
2, in the patient and her father. To our knowledge, this is the
first report of a novel heterozygous deletion in the SAG gene
identified using qPCR and the first case of Oguchi’s disease
found in a Chinese family.
This deletion was predicted to eliminate the entire exon
2 of 103 nucleotides (nt) with the AUG initiation site in the
mature mRNA of SAG and cause the use of downstream
alternative AUG codons (Figure 6). The eukaryotic ribosomes
are loaded on the 5′-cap of the mutant mRNA, scan for the
translation initiation signal (TIS), and initiate the first AUG
codon they encounter [22]. The first downstream AUG codon
out  of  frame  located  in  the  exon  3  is  recognized  by  the
ribosome, initiating the translation of its open reading frame
(ORF). A short peptide of 19 amino acids is produced, which
Figure 3. Mutation analysis of the SAG
gene in a Chinese family with Oguchi’s
disease. A: The family pedigree with the
patient indicated with a filled symbol.
B:  Overview  of  the  SAG  nucleotide
changes  identified  with  mutation
analysis  in  the  family  members.
Nucleotide  changes  in  the  patient
inherited from the mother are indicated
in the box. C: Chromatograms showing
the  heterozygous  SAG  mutation  c.
577C>T  (Arg193stop)  in  the  patient.
The affected genetic code is indicated in
the box.
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532is expected to stall ribosomes to its stop codon [23,24]. In
addition, the premature termination codon leads to the rapid
mRNA degradation by the pathway of the nonsense-mediated
mRNA decay (NMD) [25]. If possible, the mRNAs if not all
degraded  may  remain  connected  to  the  un-disassociated
ribosomes stalled at the stop codon of the ORF, and thus, these
ribosomes  may  resume  scanning  and  reinitiate  the  next
downstream TIS [26,27]. In this case, there would be three
additional  downstream  out-of-frame  AUG  codons  to  be
scanned by the ribosomes in the same way. And if the fifth in-
frame AUG codon has a chance to be initiated, a predicted
protein lacking 134 amino acids in the NH2 terminus would
be expressed in a dramatically reduced level. Even if the
expression  level  is  high  enough,  the  predicted  truncated
protein could be non-functional with impaired conformation
of the NH2-terminal half of the SAG protein and disrupted
interaction between the N domain and the C domain [28-31].
Interestingly, no missense mutations have been reported
so far. All the previously reported mutations, nonsense or
frameshift,  were  predicted  to  produce  truncated  proteins
lacking the COOH terminus if the transcripts of the gene were
not all degraded by NMD [1,8-16]. Even if the expression
level is high enough, the predicted truncated proteins could be
non-functional  [1,8-16].  Taken  together  with  the  novel
deletion reported in this study, these results led us to suggest
that the predicted aberrant SAG gene products with a loss of
either the COOH-terminus or the NH2-terminus caused by
nonsense mutations, frameshift mutations, or large fragment
deletions  eliminating  natural  AUG  codon,  having  great
potential to impair or abolish the function of the SAG protein
and thus cause its transcripts to be exposed to the NMD [25],
will cause Oguchi’s disease. Missense mutations that are not
the target of NMD may remain some basic function of the
SAG  protein  and  therefore  cause  mild  Oguchi’s  disease
without significant night blindness. However, more reports of
Oguchi’s  disease  may  help  to  elucidate  the  underlying
mechanism.
Recently,  two  recorded  copy  number  variants  in  the
Database of Genomic Variants (DGV), Gain_79017 [32] and
Loss_53177 [33], have been identified in normal individuals
with incidence of 2 in 90 (>2.2%) and 2 in 1,854 (1,064 plus
790; approximately 1‰), respectively. Those two variants
could be potential hot-spot rearrangement sites for Oguchi’s
disease.  The  duplication  of  the  exon  3  (Gain_79017)  is
Figure 4. Relative quantity (RQ) value and standard deviation calculated from the data of quantitative real-time PCRs for detecting possible
heterozygous deletions/duplications in the SAG exons in the patient and her father. An RQ value of about 1.0, 0.5, or 1.5 indicates the diploid
genotype, heterozygous deletion, or heterozygous duplication, respectively. A: Identification of a heterozygous deletion encompassing the
SAG exon 2 in the patient and her father. B: Validation and fine-mapping the deletion using the primers of In1, In2–1, In2–2, In2–3, In2–4,
and In2–5 located in intron 1 and intron 2. The heterozygous deletion involved In2–1, In2–2, and In2–3. Data were based on two independent
experiments. E, Exon; In, Intron. The error bar represents the standard deviation.
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533predicted to be pathogenic by inserting 61 nucleotides in the
coding region of the mRNA transcripts, causing a frameshift
effect and triggering the NMD. The loss of the exon 11 to 16
(Loss_53177) is also predicted to be pathogenic by lacking
the function of the C-terminus. Therefore, the incidence of
Oguchi’s disease caused by the SAG gene mutations could be
higher than expected. The relative low number of reports on
SAG gene mutations could partly be explained by the putative
pathogenic SAG deletions/duplications that escape the most
common mutation screening methods for detecting point or
minute mutations. The identification of the first deletion in the
SAG gene described in this study will suggest the idea that the
search for possible rearrangements in the SAG gene should be
routinely performed in all patients with Oguchi’s disease if
there is a negative result of the mutation screening of the
SAG gene in one or two alleles.
In  summary,  the  compound  heterozygosity  for  a
heterozygous nonsense mutation and a heterozygous deletion
of 3,224 bp encompassing exon 2 in the SAG gene would
putatively explain Oguchi’s disease in a Chinese family. Here,
we emphasize that qPCR analysis should be performed if the
mutation screening of the SAG gene fails to detect the aberrant
variants  in  patients  with  Oguchi’s  disease.  The  novel
heterozygous deletion in the SAG gene identified with the
qPCR method in this study will expand the spectrum of SAG
mutations associated with Oguchi’s disease, and this will help
to elucidate further the role of this gene in the etiology of
Oguchi’s disease.
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